E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Early Alzheimer's Disease (mild cognitive impairment due to AD (ie, prodromal AD) and mild dementia of the Alzheimer's type) |
|
E.1.1.1 | Medical condition in easily understood language |
Early Alzheimer's Disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012271 |
E.1.2 | Term | Dementia Alzheimer's type |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate disease modification as outlined in Liu-Seifert (2015). This will be accomplished by testing the three delayed-start hypotheses in both doses of LY3314814 across Study AZES and up to Week 26 (Visit 7) of Study AZFD.
|
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the disease modification of both
doses of LY3314814 on functional and cognitive outcomes across Study AZES and up to Week 26 (Visit 7) of Study AZFD using the primary analysis methodology.
2. The delayed start analyses as outlined above will also be examined throught Week 104(Visit 15) for cognitive and functional outcomes.
3. Collect information in order to further
characterize the safety and tolerability of
LY3314814 in patients with early AD
dementia (at the time of entry into Study
AZES) |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
- To evaluate the effect of LY3314814 on brain amyloid burden using positron emission tomography (PET) in the longitudinal PET sub-study (included in the main protocol).
- Protocol Addendum I8D-MC-AZFD(1.1) - FDG PET Imaging biomarker, v 12-Jul-2017 The objectives are to evaluate the effect of LY3314814 on brain metabolic rates using FDG
PET and to evaluate change from baseline (in Study AZES) in brain metabolism as measured by FDG PET.
- Protocol Addendum I8D-MC-AZFD (2.1) - Flortaucipir F 18 (18F-AV-1451) Tau PET Imaging Biomarker, v 12-Jul-2017. The objective is to evaluate change from baseline (in Study AZES) in tau as measured by flortaucipir F 18 PET.
-Protocol Addendum I8D-MC-AZFD(3.1)
Genetics v 12-Jul-2017: being conducted to collect and store whole blood
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) samples for future investigation of
variable response to LY3314814 and genetic variants thought to play a role in Alzheimer’s
disease (AD) and neurodegeneration. |
|
E.3 | Principal inclusion criteria |
Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed start I8D-MC-AZFD |
|
E.4 | Principal exclusion criteria |
Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Delayed start analysis on the ADAS-Cog13
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. V. 5, 7 and at early discontinuation
|
|
E.5.2 | Secondary end point(s) |
1. Delayed start analysis on the ADCS-iADL
2. Delayed start analysis on the FAQ
3. Delayed start analysis on the iADRS
4. Delayed start analysis on the MMSE
5. Delayed start analysis on the ADAS-Cog13
Standard safety assessments:
6. Spontaneously reported AEs
7. Clinical laboratory tests
8. Vital signs
9. Body weight
10. 12-lead ECGs
11. Physical examinations including neurological examinations
Additional safety assessments:
12. Eye examinations
13. Skin examinations
14. Serial MRI
15. Columbia-Suicide Severity Rating Scale (C-SSRS) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. V. 7, 11, 13, 15 & early discontinuation
2. V. 7, 11, 13, 15 & early discontinuation
3. V. 7, 11, 13, 15 & early discontinuation
4. V. 5, 7, 11, 13, 15 & early discontinuation
5. V. 5, 7, 11, 13, 15 & early discontinuation
6, As observed
7. V. 3, 4, 5, 7, 9, 11, 12, 13, 14, 15 & early discontinuation
8. V. 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15 & early discontinuation & follow-up
9 V. 5, 7, 11, 15 & early discontinuation
10. V. 2, 3, 5, 7, 9, 11,13,15 & early discontinuation &f ollow-up
11. V. 3, 5, 7, 9, 11,12, 13, 14, 15 & early discontinuation
12. V. 11,15 & early discontinuation
13. V. 5, 11, 15 & early discontinuation
14. V. 11, 15 & early discontinuation
15. V. 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15 & early discontinuation & follow-up |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
LY3314814 either 20 mg or 50 mg |
|
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 113 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 113 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
France |
Germany |
Hungary |
Italy |
Japan |
Korea, Republic of |
Poland |
Romania |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |